Base editing
Beam Therapeutics Aims to Raise $500M in Underwritten Offering
The firm will use the proceeds to advance its platform technology, R&D, and pre-commercialization activities for its base-editing drugs.
In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new approach to base editing.